Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Harrop: Gene-editing in womb’s ‘Twilight Zone’ of consequences on May 17, 2019 at 1:36 am
You must sign in or register to continue reading content. The ‘internet of things’ can be used to help local governments deliver services and meet challenges. ... […]
- Living in ‘Twilight Zone’ – thanks to gene-edited babies on May 16, 2019 at 9:57 pm
This is not to be confused with editing the genes of a gravely ill adult, which affects just that one person. Dr. He evidently thought that bringing forth the first gene-edited babies — twins ... […]
- CRISPR Reveals New Cancer Drug Targets through ID of Critical Gene Fusion Regions on May 16, 2019 at 6:50 am
Through their studies, the largely U.K.-based collaborators carried out CRISPR-Cas 9 editing to identify the most important gene fusions for cancer cell survival, and tested existing anticancer ... […]
- Gene Hackers: The Young Biotech Entrepreneurs Looking To Make Billions By Editing Life Itself on May 14, 2019 at 3:04 am
W hen Rachel Haurwitz started her biology Ph.D. at the University of California, Berkeley, the award-winning biochemist Jennifer Doudna suggested Haurwitz investigate part of a bacterial immune system ... […]
- Russia joins in global gene-editing bonanza on May 14, 2019 at 2:15 am
Russia is embracing gene-editing. A 111-billion-rouble (US$1.7-billion) federal programme aims to create 10 new varieties of gene-edited crops and animals by 2020 — and another 20 by 2027. Alexey ... […]
- Google Jumps Into Gene Editing: 5 Things You Need to Know on May 13, 2019 at 6:17 am
Google makes so many side bets that it named its holding company Alphabet (NASDAQ:GOOGL)(NASDAQ:GOOG) to remind investors that bold and risky investments are going to be a constant theme. One of ... […]
- Week In Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue To Expand? News On 3 China Life Science IPOs on May 12, 2019 at 9:56 am
Zai Lab completed a $200 million follow-on financing, just eight months after its previous $150 million follow-on round. TAKE2 Health, a Hong Kong healthcare startup, in-licensed global rights to ... […]
- Gene editing fixes cystic fibrosis gene in mice before birth on May 8, 2019 at 11:08 am
Cystic fibrosis, a life-threatening inherited disorder that affects the lungs and other organs, can have such damaging effects on the body in early life that some researchers think it would be better ... […]
- Verve Therapeutics, a Gene-Editing Startup, Nabs Funding to Prevent Heart Attacks on May 7, 2019 at 7:07 pm
Verve Therapeutics Inc. has raised $58.5 million on the promise of using gene editing to lower a person’s risk of heart disease. Gene-editing companies aim to cure diseases by making precise changes ... […]
- Gene-editing startup backed by Google Ventures raises $58M on May 7, 2019 at 9:58 am
Google Ventures-backed Verve Therapeutics — which has its headquarters in Cambridge, Mass, and reserarch labs at the Pennovation Center in West Philadelphia — raised $58 million. The company is ... […]
via Bing News